Friday 6-20-2014 Mannkind Corp (MNKD) $MNKD opened
Post# of 128
Posted On: 06/20/2014 11:39:31 PM
Friday 6-20-2014 Mannkind Corp (MNKD) $MNKD opened at 10.41 hitting the high price of 10.50 and a day low of 10.17 with a total volume of 12,605,046. MNKD had a previous close of 10.52 and has been seeing an average volume of 12,461,295.
Overall Average: 64% Buy
Recent stock forum discussions about MNKD http://investorshangout.com/search?q=MNKD&...mp;yt0=Go!
MannKind Has Returned 38.8% Since SmarTrend Recommendation (MNKD)
Comtex SmarTrend(R) - Fri Jun 20, 4:49PM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 3 months, MannKind has returned 38.83% as of today's recent price of $10.35. (full story)
Biotech Stock Mailbag: Zafgen, Bluebird, MannKind
at The Street - Fri Jun 20, 7:03AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies. (full story)
Is This MannKind's Biggest Risk?
George Budwell, The Motley Fool - Motley Fool - Thu Jun 19, 6:59AM CDT
Shares of clinical-stage biotech MannKind Corp. have skyrocketed by 51% over the past month, catalyzed by a positive Advisory Committee vote for the company's inhaled insulin product, Afrezza. Since then, a contentious debate has broken out... (full story)
A Chronological History of MannKind's Missed Partnership Promises
at The Street - Tue Jun 17, 1:25PM CDT
Let's wind back the tape more than 9 years to documents the many instances in which MannKind executives made promises about partnering the inhaled insulin Afrezza. (full story)
After Yesterday's Rally of 1.24% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Jun 16, 5:16PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $10.45 to a high of $10.80. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $10.54 on volume of 8.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
3 Stocks with FDA Catalysts Incoming
Alexander Maxwell, The Motley Fool - Motley Fool - Mon Jun 16, 3:31PM CDT
For biotech investors, no catalyst can match the FDA’s decision on drug approval (known as the Prescription Drug User Fee Act, or PDUFA date). The FDA's decision represents the culmination of years of clinical research (not to mention millions of... (full story)
Will These 3 Products Revolutionize Diabetes Treatment?
Todd Campbell, The Motley Fool - Motley Fool - Sun Jun 15, 2:45PM CDT
Health-care payers already spend more per member on diabetes medicine than for any other disease, and that spending is likely to grow substantially as the number of people diagnosed with the disease climbs from 366 million to 552 million by 2030. ... (full story)
'Fast Money' Recap: The Market Shrugs Off Iraq, for Now
at The Street - Sat Jun 14, 4:00AM CDT
The trading panel looked at Priceline's acquisition of OpenTable and what's going on with Groupon. (full story)
Friday's Top Upgrades (and Downgrades): MannKind, athenahealth, and Scorpio Tankers
Rich Smith, The Motley Fool - Motley Fool - Fri Jun 13, 2:42PM CDT
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines feature new buy ratings for two companies in the health care sector, inhalable insulin... (full story)
36.7% Return Seen to Date on SmarTrend MannKind Call (MNKD)
Comtex SmarTrend(R) - Fri Jun 13, 11:02AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 2 months, MannKind has returned 36.70% as of today's recent price of $10.19. (full story)
Why Mankind (MNKD) Stock Is Up Today
at The Street - Fri Jun 13, 10:20AM CDT
Mankind (MNKD) shares are up after being imitated with an 'outperform' rating by analysts at RBC Capital. (full story)
MannKind Falls 5.49% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 12, 4:38PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $9.70 to a high of $10.45. Yesterday, the shares fell 5.5%, which took the trading range below the 3-day low of $10.10 on volume of 14.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
MannKind Corporation's Date With Destiny
Brian Orelli, The Motley Fool - Motley Fool - Wed Jun 11, 7:01PM CDT
Editor's Note: MannKind's PDUFA date is July 15th -- it was accidentally noted as June 15th. The Fool regrets the error. MannKind 's PDUFA date is July 15, so we'll be watching carefully to see whether the Food and Drug Administration will... (full story)
3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Jun 08, 8:00AM CDT
What a week for the major indexes! The S&P 500 and Dow both ended at record highs. The success of the broader markets paled in comparison to a handful of health-care stocks, though. One of this week's soaring stocks received good news from... (full story)
May's 3 Best Biotech Stocks
Todd Campbell, The Motley Fool - Motley Fool - Fri Jun 06, 5:00PM CDT
Last month, shares in most biotech companies moved higher as investors began returning to the basket following a significant drop in the first quarter. Among those leading the move higher were MannKind , Intrexon Corp , and Ophthotech Corp . ... (full story)
Uptrend Call Working As MannKind Stock Rises 33.1% (MNKD)
Comtex SmarTrend(R) - Fri Jun 06, 9:40AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 2 months, MannKind has returned 33.08% as of today's recent price of $9.92. (full story)
Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition
at The Street - Fri Jun 06, 9:32AM CDT
I've been getting so much hate mail and nasty tweets lately, I thought it would be fun to throw them all into a single column for funny Friday read. There's probably something deeper to be said about market psychology and what an uptick in hate mail... (full story)
Critical Alerts For Netflix, MannKind, Dish Network, Illumina, and Anheuser-Busch InBev Technology Released By InvestorsObserver
PR Newswire - Fri Jun 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for NFLX, MNKD, DISH, ILMN, and BUD. (full story)
MannKind Hits 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 7:00AM CDT
Shares of MannKind (MNKD) hit a 52-week high of $11.11 during the trading session on Jun 5 (full story)
Most active Nasdaq-traded stocks
AP - Thu Jun 05, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading: (full story)
Overall Average: 64% Buy
Recent stock forum discussions about MNKD http://investorshangout.com/search?q=MNKD&...mp;yt0=Go!
MannKind Has Returned 38.8% Since SmarTrend Recommendation (MNKD)
Comtex SmarTrend(R) - Fri Jun 20, 4:49PM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 3 months, MannKind has returned 38.83% as of today's recent price of $10.35. (full story)
Biotech Stock Mailbag: Zafgen, Bluebird, MannKind
at The Street - Fri Jun 20, 7:03AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies. (full story)
Is This MannKind's Biggest Risk?
George Budwell, The Motley Fool - Motley Fool - Thu Jun 19, 6:59AM CDT
Shares of clinical-stage biotech MannKind Corp. have skyrocketed by 51% over the past month, catalyzed by a positive Advisory Committee vote for the company's inhaled insulin product, Afrezza. Since then, a contentious debate has broken out... (full story)
A Chronological History of MannKind's Missed Partnership Promises
at The Street - Tue Jun 17, 1:25PM CDT
Let's wind back the tape more than 9 years to documents the many instances in which MannKind executives made promises about partnering the inhaled insulin Afrezza. (full story)
After Yesterday's Rally of 1.24% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Jun 16, 5:16PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $10.45 to a high of $10.80. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $10.54 on volume of 8.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
3 Stocks with FDA Catalysts Incoming
Alexander Maxwell, The Motley Fool - Motley Fool - Mon Jun 16, 3:31PM CDT
For biotech investors, no catalyst can match the FDA’s decision on drug approval (known as the Prescription Drug User Fee Act, or PDUFA date). The FDA's decision represents the culmination of years of clinical research (not to mention millions of... (full story)
Will These 3 Products Revolutionize Diabetes Treatment?
Todd Campbell, The Motley Fool - Motley Fool - Sun Jun 15, 2:45PM CDT
Health-care payers already spend more per member on diabetes medicine than for any other disease, and that spending is likely to grow substantially as the number of people diagnosed with the disease climbs from 366 million to 552 million by 2030. ... (full story)
'Fast Money' Recap: The Market Shrugs Off Iraq, for Now
at The Street - Sat Jun 14, 4:00AM CDT
The trading panel looked at Priceline's acquisition of OpenTable and what's going on with Groupon. (full story)
Friday's Top Upgrades (and Downgrades): MannKind, athenahealth, and Scorpio Tankers
Rich Smith, The Motley Fool - Motley Fool - Fri Jun 13, 2:42PM CDT
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines feature new buy ratings for two companies in the health care sector, inhalable insulin... (full story)
36.7% Return Seen to Date on SmarTrend MannKind Call (MNKD)
Comtex SmarTrend(R) - Fri Jun 13, 11:02AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 2 months, MannKind has returned 36.70% as of today's recent price of $10.19. (full story)
Why Mankind (MNKD) Stock Is Up Today
at The Street - Fri Jun 13, 10:20AM CDT
Mankind (MNKD) shares are up after being imitated with an 'outperform' rating by analysts at RBC Capital. (full story)
MannKind Falls 5.49% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 12, 4:38PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $9.70 to a high of $10.45. Yesterday, the shares fell 5.5%, which took the trading range below the 3-day low of $10.10 on volume of 14.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
MannKind Corporation's Date With Destiny
Brian Orelli, The Motley Fool - Motley Fool - Wed Jun 11, 7:01PM CDT
Editor's Note: MannKind's PDUFA date is July 15th -- it was accidentally noted as June 15th. The Fool regrets the error. MannKind 's PDUFA date is July 15, so we'll be watching carefully to see whether the Food and Drug Administration will... (full story)
3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Jun 08, 8:00AM CDT
What a week for the major indexes! The S&P 500 and Dow both ended at record highs. The success of the broader markets paled in comparison to a handful of health-care stocks, though. One of this week's soaring stocks received good news from... (full story)
May's 3 Best Biotech Stocks
Todd Campbell, The Motley Fool - Motley Fool - Fri Jun 06, 5:00PM CDT
Last month, shares in most biotech companies moved higher as investors began returning to the basket following a significant drop in the first quarter. Among those leading the move higher were MannKind , Intrexon Corp , and Ophthotech Corp . ... (full story)
Uptrend Call Working As MannKind Stock Rises 33.1% (MNKD)
Comtex SmarTrend(R) - Fri Jun 06, 9:40AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 2 months, MannKind has returned 33.08% as of today's recent price of $9.92. (full story)
Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition
at The Street - Fri Jun 06, 9:32AM CDT
I've been getting so much hate mail and nasty tweets lately, I thought it would be fun to throw them all into a single column for funny Friday read. There's probably something deeper to be said about market psychology and what an uptick in hate mail... (full story)
Critical Alerts For Netflix, MannKind, Dish Network, Illumina, and Anheuser-Busch InBev Technology Released By InvestorsObserver
PR Newswire - Fri Jun 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for NFLX, MNKD, DISH, ILMN, and BUD. (full story)
MannKind Hits 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 7:00AM CDT
Shares of MannKind (MNKD) hit a 52-week high of $11.11 during the trading session on Jun 5 (full story)
Most active Nasdaq-traded stocks
AP - Thu Jun 05, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading: (full story)
(0)
(0)MannKind Corporation (MNKD) Stock Research Links
Scroll down for more posts ▼